Biotechnology company developing psychedelic-inspired medicines and therapies to treat addiction and mental wellness Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) announced having released the publication of a study that compares the effects of psychedelic among healthy individuals.
The study directly compared the acute effects of Lysergic Acid Diethylamide (LSD) and psilocybin in healthy individuals. The data was published in Neuropsychopharmacology under the title ‘Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo controlled study in health subjects.’
The study shows that the major differences between LCD and psilocybin are dose-dependent rather than substance-dependent. These findings come with the potential to assist in dose finding, trial design and inform future studies evaluating the therapeutic utility of psychedelics.
“Today, we announced the peer-reviewed publication in @npp_journal of a study comparing the acute effects of LSD and psilocybin in healthy subjects. Click here to learn more about the potential therapeutic utility of #psychedelics,” posted MindMed on Twitter.
The placebo-controlled double-blind study was investigator-initiated at the University Hospital Basel. Professor Matthias Liechti M.D., University Hospital Basel served as the principal investigator in the study.
“The results in this publication continue to expand our knowledge of the differences between LSD and psilocybin with regard to their acute effects, similarities, and dose-equivalence. Although both substances are used as pharmacological tools, there are no modern studies investigating and directly comparing the acute effects of these substances within the same clinical study, using well defined doses and validated psychometric tools. Together, these results suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg psilocybin is equivalent to 150 μg LSD, making the dose equivalence of LSD to psilocybin approximately 1:200. Strikingly, there were no qualitative differences in altered states of consciousness across substances, except that the duration of action was shorter for psilocybin,” said the professor.